Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (:MHLW) approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback